China S Drug Practices And Policies

In the context of global efforts to control the production, distribution and use of narcotic drugs, China's treatment of the problem provides an important means of understanding the social, political, and economic limits of national and international policies to regulate drug practices. In the nineteenth and early twentieth centuries, China was known for its national addiction to opium, but its drug-eradication campaigns from the 1950s to the 1970s achieved unprecedented success that ultimately transformed China into a "drug-free" society. However, since the economic reforms and open-door policy of the late twentieth century, China is now facing a re-emergence of the production, use and trafficking of narcotic drugs. Employing case studies and a comparative historical approach, and drawing on a variety of data sources including historical records, official crime data only recently made available, and news reports, this book is the first English-language publication to provide such a comprehensive documentation and analysis of the nature of China's legal regulation of controlled substances. The authors also offer theoretical approaches for studying drug regulation, aspects of drug consumption cultures, the socio-political treatment of drugs during various historical periods and ongoing efforts to legislate drug trade, criminalize drug use and manage the drug addict population within national and international contexts.

In More Harm Than Good, Carter, Boyd and MacPherson take a critical look at the current state of Canadian drug policy and raise key questions about the effects of Canada’s increasing involvement in and commitment to the “war on drugs.” A primer on Canadian drug policy, the analysis in More Harm Than Good is shaped by critical sociology and feminist perspectives on drugs and incorporates insights not only from individuals who are on the front lines of drug policy in Canada — treatment and service workers — but also from those who live with the consequences of that policy on a daily basis — people who use criminalized drugs. Finally, the authors propose realistic alternatives to today’s failed policy approach. “Your book really expanded thinking and understanding and had a big influence on students critical and reflective thought. Readings sparked rich conversations about their own hopes and wishes for the field, broader social and political responses and the impact on youth and families affected by substances.” - Stephanie McCune, University of Victoria Please note: an error occurred with the printing of this book, and one of the sidebars was not printed. It is available to download here. We sincerely apologize for this oversight.

Treating Drug Problems, Volume 2 presents a wealth of incisive and accessible information on the issue of drug abuse and treatment in America. Several papers lay bare the relationship between drug treatment and other aspects of drug policy, including a powerful overview of twentieth century narcotics use in America and a unique account of how the federal government has built and managed the drug treatment system from the 1960s to the present. Two papers focus on the criminal justice system. The remaining papers focus on Employer policies and practices toward illegal drugs. Patterns and cycles of cocaine use in subcultures and the popular culture. Drug treatment from a marketing, supply-and-demand perspective, including an analysis of policy options. Treating Drug Problems, Volume 2 provides important information to policy makers and administrators, drug treatment specialists, and researchers.

The 12th volume of International Development Policy explores the relationship between international drug policy and development goals, both current and within a historical perspective. Contributions address the drugs and development nexus from a range of critical viewpoints, highlighting gaps and contradictions, as well as exploring strategies and opportunities for enhanced linkages between drug control and development programming. Criminalisation and coercive law enforcement-based responses in international and national level drug control are shown to undermine peace, security and development objectives. Contributors include: Kenza Afsahi, Damon Barrett, David Bewley-Taylor, Daniel Brombacher, Julia Buxton, Mary Chinery-Hesse, John Collins, Joanne Csete, Sarah David, Ann Fordham, Corina Giacomello, Martin Jelsma, Sylvia Kay, Diederik Lohman, David Mansfield, José Ramos-Horta, Tuesday Reitano, Andrew Scheibe, Shaun Shelly, Khalid Tinasti, and Anna Versfeld.

While there have always been norms and customs around the use of drugs, explicit public policies--regulations, taxes, and prohibitions--designed to control drug abuse are a more recent phenomenon. Those policies sometimes have terrible side-effects: most prominently the development of criminal enterprises dealing in forbidden (or untaxed) drugs and the use of the profits of drug-dealing to finance insurgency and terrorism. Neither a drug-free world nor a world of free drugs seems to be on offer, leaving citizens and officials to face the age-old problem: What are we going to do about drugs? In Drugs and Drug Policy, three noted authorities survey the subject with exceptional clarity, in this addition to the acclaimed series, What Everyone Needs to Know®. They begin, by defining "drugs," examining how they work in the brain, discussing the nature of addiction, and exploring the damage they do to users. The book moves on to policy, answering questions about legalization, the role of criminal prohibitions, and the relative legal tolerance for alcohol and tobacco. The authors then dissect the illicit trade, from street dealers to the flow of money to the effect of catching kingpins, and show the precise nature of the relationship between drugs and crime. They examine treatment, both its effectiveness and the role of public policy, and discuss the beneficial effects of some abusable substances. Finally they move outward to look at the role of drugs in our foreign policy, their relationship to terrorism, and the ugly politics that surround the issue. Crisp, clear, and comprehensive, this is a handy and up-to-date overview of one of the most pressing topics in today's world. What Everyone Needs to Know® is a registered trademark of Oxford University Press.

Drugs and Drug Policy: The Control of Consciousness Alteration provides a cross-national perspective on the regulation of drug use by examining and critiquing drug policies in the United States and abroad in terms of their scope, goals, and effectiveness. In this engaging text, authors Clayton J. Mosher and Scott Akins discuss the physiological, psychological, and behavioral effects of legal and illicit drugs; the patterns and correlates of use; and theories of the "causes" of drug use. Key Features: * Offers more coverage of drug policy issues than competitive books: This book addresses the number of significant developments over the last few decades that suggest the dynamics of drug use and policies to deal with drug use are at a critical juncture. The book also considers the issue of "American exceptionalism" with respect to drug policies through a detailed analysis of emerging drug polices in other Western nations. * Makes explicit comparisons between legal and illegal drugs: Due to their prevalence of use, this book devotes considerable attention to the use and regulation of legal drugs in society. The book illustrates that commonly prescribed medications are similar to drugs that are among the most feared and harshly punished in society and that drug-related problems do not necessarily result from particular drugs, but from how drugs are used. * Includes many pedagogical tools: With chapter opening photos and more photos throughout, this text presents material in a student- friendly fashion. Highlight boxes provide interesting examples for readers; encourage further emphasis on issues; and serve as important topics for in class writing exercises. In addition, Internet exercises and review questions reinforce key points made in the chapter and prompt classroom discussion.

Illegal psychoactive substances and illicit prescription drugs are currently used on a daily basis all over the world. Affecting public health and social welfare, illicit drug use is linked to disease, disability, and social problems. Faced with an increase in usage, national and global policymakers are turning to addiction science for guidance on how to create evidence-based drug policy. Drug Policy and the Public Good is an objective analytical basis on which to build global drug policies. It presents the accumulated scientific knowledge on drug use in relation to policy development on a national and international level. By also revealing new epidemiological data on the global dimensions of drug misuse, it questions existing regulations and highlights the growing need for evidence-based, realistic, and coordinated drug policy. A critical review of cumulative scientific evidence, Drug Policy and the Public Good discusses four areas of drug policy; primary prevention programs in schools and other settings; supply reduction programs, including legal enforcement and drug interdiction; treatment interventions and harm reduction approaches; and control of the legal market through prescription drug regimes. In addition, it analyses the current state of global drug policy, and advocates improvements in the drafting of public health policy. Drug Policy and the Public Good is a global source of information and inspiration for policymakers involved in public health and social welfare. Presenting new research on illicit and prescription drug use, it is also an essential tool for academics, and a significant contribution to the translation of addiction research into effective drug policy.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.